Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...

Resilience has characterized many people who have dealt with chronic health challenges, and it would be hard to find someone ...

Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...

It may not be something you like to talk about, but if you have gastrointestinal (GI) problems, your symptoms may be far more ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...

A new test developed in the UK can accurately predict whether high-risk patients will develop bowel cancer, also known as ...